Maryland is currently home to 2668 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Baltimore, Bethesda, Rockville and Annapolis. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Magnetic Resonance Spectroscopy Studies of Cardiac Muscle Metabolism
NCT00181259
Recruiting
The metabolism of the heart provides the chemical energy needed to fuel ongoing normal heart contraction. Magnetic resonance spectroscopy is a technique used in a MRI scanner that can be used to measure and study heart metabolism directly but without blood sampling or obtaining tissue biopsies. One of the hypotheses this study aims to investigate is whether energy metabolism is reduced in heart failure and whether that contributes to the poor heart function.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/09/2025
Locations: Johns Hopkins Medical Institutions, Baltimore, Maryland
Conditions: Heart Failure, Congestive
Register for Updates
Genetic Basis of Immunodeficiency
NCT00055172
Recruiting
This study will examine the role of hereditary factors in different forms of severe combined immunodeficiency (SCID). Patients with immunodeficiencies may be eligible for this study. Candidates include: * Patients with diminished numbers of T cells or NK cells or both, or * Patients with normal T cell and NK cell numbers but diminished T cell, B cell, or NK cell function. Relatives of patients will also be studied. Participants will have blood samples collected for genetic analysis in studie... Read More
Gender:
ALL
Ages:
Between 6 months and 99 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Severe Combined Immunodeficiency
Register for Updates
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders
NCT00029965
Recruiting
Study description: This is a natural history study that will evaluate any patient with enzyme or DNA confirmed GM1 or GM2 gangliosidosis, sialidosis or galactosialidosis. Patients may be evaluated every 6 months for infantile onset disease, yearly for juvenile onset and approximately every two years for adult-onset disease as long as they are clinically stable to travel. Data will be evaluated serially for each patient, and cross-sectionally for patients of similar ages and genotypes. Genotype-... Read More
Gender:
ALL
Ages:
Between 1 day and 100 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Neurological Regression, Myoclonus, Cherry Red Spot, Brain Atrophy
Register for Updates
Study of Inherited Neurological Disorders
NCT00004568
Recruiting
This study is designed to learn more about the natural history of inherited neurological disorders and the role of heredity in their development. It will examine the genetics, symptoms, disease progression, treatment, and psychological and behavioral impact of diseases in the following categories: hereditary peripheral neuropathies; hereditary myopathies; muscular dystrophies; hereditary motor neuron disorders; mitochondrial myopathies; hereditary neurocognitive disorders; inherited neurological... Read More
Gender:
ALL
Ages:
Between 2 years and 120 years
Trial Updated:
07/09/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Motor Neuron Disease, Muscular Disease, Muscular Dystrophy, Peripheral Nervous System Disease
Register for Updates
Safety and Efficacy of VDPHL01 in Males With AGA
NCT06972264
Recruiting
This study will evaluate the safety and efficacy of VDPHL01 in male subjects with Androgenetic Alopecia (AGA). AGA (or male pattern baldness) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablet is an investigational oral drug to treat male pattern baldness. This multi-center, double blind, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, mont... Read More
Gender:
MALE
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Site 84, Glenn Dale, Maryland
Conditions: Androgenetic Alopecia, AGA, Male Pattern Baldness
Register for Updates
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE)
NCT06719141
Recruiting
This (DEEp OCEAN Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DEE. The study consists of 3 main phases: Screening, Titration period, Maintenance period, followed by a Taper period and Follow-Up. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA07, Bethesda, Maryland
Conditions: Developmental and Epileptic Encephalopathy
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA07, Bethesda, Maryland
Conditions: Dravet Syndrome
Register for Updates
A Human Challenge Study to Assess Protection of a Shigella Tetravalent Bioconjugate Vaccine
NCT06615375
Recruiting
In this challenge study, the bioconjugate candidate vaccine Shigella4V2 will be tested for its ability to induce an immune response that protects healthy adult volunteers from infection with a wild-type Shigella sonnei strain compared to participants receiving placebo.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
07/08/2025
Locations: Johns Hopkins Center for Immunization Research, Baltimore, Maryland
Conditions: Shigellosis
Register for Updates
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/08/2025
Locations: Johns Hopkins Hospital, Baltimore, Maryland
Conditions: Prader-Willi Syndrome
Register for Updates
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
NCT06339177
Recruiting
Background: Hemophagocytic lymphohistiocytosis (HLH) is a disease caused by disrupted immune function. People with HLH are prone to fevers and illnesses, which can be fatal. Some people develop a genetic form of this disease (pHLH), but researchers do not understand why some other people develop a nongenetic form (sHLH). They also do not have good ways to diagnose and treat sHLH. Objective: To learn about sHLH and why some people get it and others do not. Eligibility: Adults aged 18 years a... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
07/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphohistiocytosis, Hemophagocytic, Secondary Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Hyperinflammatory Syndromes
Register for Updates
ALIGN: Aligning Medications With What Matters Most (Demonstration)
NCT06335953
Recruiting
The goal of this clinical trial is to test the effectiveness of a pharmacist-led, primary care-based de-prescribing intervention for people living with dementia (PLWD) and the person's care partners. The intervention consists of the following strategies: 1) a de-prescribing educational brochure designed to activate the patient and care partner; 2) a single telehealth visit in which an embedded clinical pharmacist discusses the benefits and harms of the patient's medications with the patient and... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
07/08/2025
Locations: Johns Hopkins Community Physicians, Baltimore, Maryland
Conditions: Polypharmacy, Alzheimer's Disease and Related Dementias, Mild Cognitive Impairment
Register for Updates
Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated Cytopenias
NCT05502783
Recruiting
Background: People who have a blood stem cell transplant can sometimes develop cytopenia. This means that their levels of one or more types of blood cell, such as the red cells or platelets, are lower than they should be. This can occur because a person s immune system might attack these cells after a stem cell transplant. Cytopenia can lead to anemia, severe bleeding, infections, and other problems. Treatments are needed to help keep blood cell levels stable after blood stem cell transplant.... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/08/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Immune Mediated Anemia, Immune Mediated Thrombocytopenia, Chronic GVHD
Register for Updates